Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders

• Main Authors: Cristina Maccallini, Rosa Amoroso
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2016-01-01
• Series: Neural Regeneration Research
• Subjects: amidines; carbonic anhydrase; inhibitors; neurological diseases; neuronal nitric oxide synthase; NMDAR; PSD95
• Online Access: http://www.nrronline.org/article.asp?issn=1673-5374;year=2016;volume=11;issue=11;spage=1731;epage=1734;aulast=Maccallini

The management of neurological disorders have huge and increasing human and economic costs. Despite this, there is a scarcity of effective therapeutics, and there is an extreme urgency for new and real treatments. In this short review we analyze some promising advancements in the search of new bioactive molecules targeting neuronal nitric oxide synthase (nNOS), an enzyme deputed to the biosynthesis of nitric oxide (NO). In different conditions of neuronal damages, this molecule is overproduced, contributing to the pathogenesis and progression of neuronal diseases. Two main approaches to modulate nNOS are discussed: a first one consisting in the direct inhibition of the enzyme by means of small organic molecules, which can be also active against other different targets involved in such diseases. A second section is dedicated to molecules able to prevent the formation of the ternary complex N-methyl-D-aspartate (NMDA)-type glutamate receptors, postsynaptic density-95 (PSD95) protein-nNOS, which is necessary to activate the latter for the biosynthesis of NO.